Literature DB >> 11046025

Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization.

M Migliaccio1, M Amacker, T Just, P Reichenbach, D Valmori, J C Cerottini, P Romero, M Nabholz.   

Abstract

Like most somatic human cells, T lymphocytes have a limited replicative life span. This phenomenon, called senescence, presents a serious barrier to clinical applications that require large numbers of Ag-specific T cells such as adoptive transfer therapy. Ectopic expression of hTERT, the human catalytic subunit of the enzyme telomerase, permits fibroblasts and endothelial cells to avoid senescence and to become immortal. In an attempt to immortalize normal human CD8(+) T lymphocytes, we infected bulk cultures or clones of these cells with a retrovirus transducing an hTERT cDNA clone. More than 90% of transduced cells expressed the transgene, and the cell populations contained high levels of telomerase activity. Measuring the content of total telomere repeats in individual cells (by flowFISH) we found that ectopic hTERT expression reversed the gradual loss of telomeric DNA observed in control populations during long term culture. Telomere length in transduced cells reached the levels observed in freshly isolated normal CD8(+) lymphocytes. Nevertheless, all hTERT-transduced populations stopped to divide at the same time as nontransduced or vector-transduced control cells. When kept in IL-2 the arrested cells remained alive. Our results indicate that hTERT may be required but is not sufficient to immortalize human T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046025     DOI: 10.4049/jimmunol.165.9.4978

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells.

Authors:  M J O'Hare; J Bond; C Clarke; Y Takeuchi; A J Atherton; C Berry; J Moody; A R Silver; D C Davies; A E Alsop; A M Neville; P S Jat
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

2.  Role of p14(ARF) in replicative and induced senescence of human fibroblasts.

Authors:  W Wei; R M Hemmer; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

3.  P16/p53 expression and telomerase activity in immortalized human dental pulp cells.

Authors:  Obi Egbuniwe; Bernadine D Idowu; Juan M Funes; Andrew D Grant; Tara Renton; Lucy Di Silvio
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 4.  Telomere and adaptive immunity.

Authors:  Nan-ping Weng
Journal:  Mech Ageing Dev       Date:  2007-12-08       Impact factor: 5.432

Review 5.  Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases.

Authors:  Michael Patrick; Nan-Ping Weng
Journal:  Cell Immunol       Date:  2019-09-19       Impact factor: 4.868

6.  Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.

Authors:  Xinglei Shen; Juhua Zhou; Karen S Hathcock; Paul Robbins; Daniel J Powell; Steven A Rosenberg; Richard J Hodes
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

7.  Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.

Authors:  Mirabelle Dagarag; Hwee Ng; Rachel Lubong; Rita B Effros; Otto O Yang
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

Review 9.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

10.  Telomerase activation in the treatment of aging or degenerative diseases: a systematic review.

Authors:  P Prieto-Oliveira
Journal:  Mol Cell Biochem       Date:  2020-10-01       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.